Bolt Biotherapeutics Asset Resilience Ratio
Bolt Biotherapeutics asset resilience ratio. Bolt Biotherapeutics (BOLT) has an Asset Resilience Ratio of 27.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bolt Biotherapeutics liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bolt Biotherapeutics (2018–2025)
Asset resilience ratio of Bolt Biotherapeutics from 2018 to 2025. This chart shows how Bolt Biotherapeutics's Asset Resilience Ratio has changed over time. Read debt load of Bolt Biotherapeutics for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bolt Biotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Bolt Biotherapeutics.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.80 Million | 27.85% |
| Total Liquid Assets | $15.80 Million | 27.85% |
Asset Resilience Insights
- Very High Liquidity: Bolt Biotherapeutics maintains exceptional liquid asset reserves at 27.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bolt Biotherapeutics Industry Peers by Asset Resilience Ratio
Compare Bolt Biotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Bolt Biotherapeutics Asset Resilience Ratio by Year (2018–2025)
Bolt Biotherapeutics asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Bolt Biotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.85% | $15.80 Million | $56.75 Million | -12.42pp |
| 2024-12-31 | 40.27% | $40.12 Million | $99.63 Million | -16.92pp |
| 2023-12-31 | 57.19% | $91.38 Million | $159.78 Million | -12.89pp |
| 2022-12-31 | 70.08% | $159.64 Million | $227.81 Million | +18.46pp |
| 2021-12-31 | 51.62% | $158.84 Million | $307.72 Million | +14.46pp |
| 2020-12-31 | 37.16% | $17.30 Million | $46.54 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $48.45 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $15.97 Million | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more